Related Experiment Video
Updated: Oct 4, 2025
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.4K
HbA1c, Coronary atheroma progression and cardiovascular outcomes
Iryna Dykun1,2, Ozgur Bayturan3, Julie Carlo1
1C5Research, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH.
American Journal of Preventive Cardiology
|February 3, 2022
Summary
Higher on-treatment hemoglobin A1c (HbA1c) levels are linked to increased coronary artery plaque buildup and major adverse cardiovascular events (MACE). This suggests glycemic control directly impacts cardiovascular health, independent of other risk factors.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Glycemic control is crucial for managing diabetes and preventing complications.
- The direct impact of on-treatment hemoglobin A1c (HbA1c) on coronary atheroma progression and major adverse cardiovascular events (MACE) remains an area of investigation.
Purpose of the Study:
- To investigate the independent association between on-treatment HbA1c levels and coronary atheroma progression.
- To assess the relationship between on-treatment HbA1c levels and the incidence of MACE.
Main Methods:
- A post-hoc pooled analysis of seven prospective, randomized trials using serial coronary intravascular ultrasonography (IVUS).
- Percent atheroma volume (PAV) was measured to assess plaque burden.
- Multivariable mixed modeling and Cox proportional hazard models were employed to analyze associations.
Main Results:
- In 3,312 patients, higher on-treatment HbA1c levels were independently associated with increased annualized changes in PAV (beta: 0.13 [0.08, 0.19], p < 0.001).
- On-treatment HbA1c levels were also independently associated with a higher incidence of MACE (HR: 1.13 [1.04, 1.23], p = 0.005).
Conclusions:
- Elevated on-treatment HbA1c levels are significantly associated with coronary atheroma progression and adverse cardiovascular outcomes, irrespective of other risk factor control.
- These findings support a direct effect of glycemic control on coronary atheroma and atherosclerotic events, underscoring the rationale for therapies targeting glycemic modulation.
Keywords:
ACS, acute coronary syndromeAQUARIUS, Aliskiren Quantative Atherosclerosis Regression Intravascular Ultrasound StudyASCVD, atherosclerotic cardiovascular diseaseBMI, body mass indexCVD, cardiovascular diseaseCoronary atheroma progressionDiabetes mellitusGLAGOV, Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular UltrasoundHDL-C, high-density lipoprotein cholesterolHbA1cHbA1c, hemoglobin A1cIBIS 2, The Integrated Biomarkers and Imaging Study-2IVUSIVUS, intravascular ultrasonographyLDL-C, lipoprotein cholesterolMACEMACE, major adverse cardiovascular eventsNORMALISE, Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic EvaluationPAV, percent atheroma volumePERISCOPE, Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective EvaluationPVD, peripheral vascular diseaseREVERSAL, Reversal of Atherosclerosis With Aggressive Lipid LoweringSATURN, The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatinSTRADIVARIUS, Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabont – The Intravascular Ultrasound StudyTG, triglyceridesUKPDS, UK Prospective Diabetes StudyhsCRP, high-sensitivity-CRPMore Related Videos
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
234
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
234
01:26Coronary Artery Disease IV: Preventive Measures
172
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
172
01:26Coronary Artery Disease II: Pathophysiology
73
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
73
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
72
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
72
01:26Atherosclerosis III: Management
58
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
58
01:27Coronary Artery Disease V: Interprofessional Care
56
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
56